Atrial Fibrillation and Ischemic Stroke despite Oral Anticoagulation

Patients with atrial fibrillation (AF) experiencing ischemic stroke despite oral anticoagulation (OAC), i.e., breakthrough strokes, are not uncommon, and represent an important clinical subgroup in view of the consistently high risk of stroke recurrence and mortality. The understanding of the heterogenous potential mechanism underlying OAC failure is essential in order to implement specific therapeutic measures aimed at reducing the risk of recurrent ischemic stroke. However, due to the incomplete comprehension of this phenomenon and the limited available data, secondary stroke prevention in such high-risk patients represents a clinical dilemma. There are several available strategies to prevent ischemic stroke recurrence in AF patients with breakthrough stroke in the absence of competing causes unrelated to AF, and these include continuation or change in the type of OAC, addition of antiplatelet therapy, left atrial appendage closure, or any combination of the above options. However, due to the limited available data, the latest guidelines do not provide any specific recommendations about which of the above strategies may be preferred. This review describes the incidence, the clinical impact and the potential mechanisms underlying OAC failure in AF patients. Furthermore, the evidence supporting each of the above therapeutic options for secondary stroke prevention and the potential future directions will be discussed.

[1]  D. Werring,et al.  Early versus Later Anticoagulation for Stroke with Atrial Fibrillation. , 2023, The New England journal of medicine.

[2]  H. Ko,et al.  Association of Alternative Anticoagulation Strategies and Outcomes in Patients With Ischemic Stroke While Taking a Direct Oral Anticoagulant , 2023, Neurology.

[3]  A. Huber,et al.  Impact of Preprocedural Computed Tomography on Left Atrial Appendage Closure Success: A Swiss-Apero Trial Subanalysis. , 2023, JACC. Cardiovascular interventions.

[4]  S. Connolly,et al.  Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation. , 2023, European heart journal.

[5]  M. Price,et al.  SCAI/HRS expert consensus statement on transcatheter left atrial appendage closure. , 2023, Heart rhythm.

[6]  J. Saw,et al.  Left atrial appendage occlusion. , 2023, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[7]  D. Werring,et al.  Left atrial appendage occlusion versus standard of care in patients with atrial fibrillation and a prior thrombo-embolic event despite oral anticoagulant therapy: a propensity score matched comparison , 2022, European Heart Journal.

[8]  B. Norrving,et al.  Early Versus Delayed Non–Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study , 2022, Circulation.

[9]  Eric E. Smith,et al.  Antithrombotic dilemmas in stroke medicine: new data, unsolved challenges , 2022, Journal of Neurology, Neurosurgery, and Psychiatry.

[10]  K. Furie,et al.  Recurrent Ischemic Stroke and Bleeding in Patients With Atrial Fibrillation Who Suffered an Acute Stroke While on Treatment With Nonvitamin K Antagonist Oral Anticoagulants: The RENO-EXTEND Study , 2022, Stroke.

[11]  H. Crijns,et al.  The Increasing Role of Rhythm Control in Patients With Atrial Fibrillation: JACC State-of-the-Art Review. , 2022, Journal of the American College of Cardiology.

[12]  C. Nolte,et al.  Aetiology, secondary prevention strategies and outcomes of ischaemic stroke despite oral anticoagulant therapy in patients with atrial fibrillation , 2022, Journal of Neurology, Neurosurgery, and Psychiatry.

[13]  A. Huber,et al.  Watchman FLX vs. Watchman 2.5 in a Dual-Center Left Atrial Appendage Closure Cohort: the WATCH-DUAL study. , 2022, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[14]  S. Bangalore,et al.  Residual stroke risk after left atrial appendage closure in patients with prior Oral anticoagulation failure. , 2022, International journal of cardiology.

[15]  Rizwan Kalani,et al.  Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association , 2022, Circulation.

[16]  J. Uhm,et al.  Risks and Benefits of Early Rhythm Control in Patients With Acute Strokes and Atrial Fibrillation: A Multicenter, Prospective, Randomized Study (the RAFAS Trial) , 2022, Journal of the American Heart Association.

[17]  L. Räber,et al.  Left atrial appendage closure for thrombus trapping: the international, multicentre TRAPEUR registry. , 2021, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[18]  A. Huber,et al.  Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: Primary Results of the SWISS-APERO Randomized Clinical Trial , 2021, Circulation.

[19]  J. Sinisalo,et al.  Left Atrial Appendage Occlusion versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation: Rationale and Design of the Multicenter Randomized Occlusion-AF Trial. , 2021, American heart journal.

[20]  Eric E. Smith,et al.  Ischaemic stroke in anticoagulated patients with atrial fibrillation , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

[21]  L. Räber,et al.  Impact of Echocardiographic Guidance on Safety and Efficacy of Left Atrial Appendage Closure: An Observational Study. , 2021, JACC. Cardiovascular interventions.

[22]  J. Healey,et al.  Antiplatelet Therapy in Patients with Atrial Fibrillation: A Systematic Review and Metaanalysis of Randomized Trials. , 2021, European heart journal. Cardiovascular pharmacotherapy.

[23]  H. Kamel,et al.  2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. , 2021, Stroke.

[24]  S. Yusuf,et al.  Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke. , 2021, The New England journal of medicine.

[25]  Eric E. Smith,et al.  Ischaemic stroke on anticoagulation therapy and early recurrence in acute cardioembolic stroke: the IAC study , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

[26]  E. Carrera,et al.  Prior Anticoagulation in Patients with Ischemic Stroke and Atrial Fibrillation , 2020, Annals of neurology.

[27]  S. Verheye,et al.  Left atrial appendage occlusion in recurrent ischaemic stroke, a multicentre experience , 2020, Acta clinica Belgica.

[28]  Jeroen J. Bax,et al.  2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). , 2020, European heart journal.

[29]  K. Furie,et al.  Factors associated with therapeutic anticoagulation status in patients with ischemic stroke and atrial fibrillation. , 2020, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[30]  R. Risso,et al.  The management of patients with acute ischemic stroke while on direct oral anticoagulants (DOACs): data from an Italian cohort and a proposed algorithm , 2020, Journal of Thrombosis and Thrombolysis.

[31]  N. Suzuki,et al.  Atrial Fibrillation-Associated Ischemic Stroke Patients With Prior Anticoagulation Have Higher Risk for Recurrent Stroke , 2020, Stroke.

[32]  D. Werring,et al.  Ischemic Stroke despite Oral Anticoagulant Therapy in Patients with Atrial Fibrillation , 2020, Annals of neurology.

[33]  B. Meier,et al.  Left atrial appendage occlusion for stroke despite oral anticoagulation (resistant stroke). Results from the Amplatzer Cardiac Plug registry. , 2020, Revista Española de Cardiología.

[34]  K. Furie,et al.  Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. , 2019, Stroke.

[35]  Hugh Calkins,et al.  Correction to: 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Circulation.

[36]  M. García-Fernández,et al.  Prevalence of extra-appendage thrombosis in non-valvular atrial fibrillation and atrial flutter in patients undergoing cardioversion: a large transoesophageal echo study. , 2019, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[37]  A. Regueiro,et al.  Left Atrial Appendage Occlusion as Adjunctive Therapy to Anticoagulation for Stroke Recurrence. , 2019, The Journal of invasive cardiology.

[38]  J. Zamorano,et al.  Oral anticoagulation and left atrial appendage closure: a new strategy for recurrent cardioembolic stroke , 2019, European journal of neurology.

[39]  J. Sargento-Freitas,et al.  Ischemic stroke in patients previously anticoagulated for non-valvular atrial fibrillation: Why does it happen? , 2019, Revista Portuguesa de Cardiologia (English Edition).

[40]  A. Luft,et al.  Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage , 2018, Annals of neurology.

[41]  Saibal Kar,et al.  5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. , 2017, Journal of the American College of Cardiology.

[42]  Michael J Pencina,et al.  Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation , 2017, JAMA.

[43]  P. Noseworthy,et al.  Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation , 2016, Journal of the American Heart Association.

[44]  Hooman Kamel,et al.  Left Atrial Appendage Function and Stroke Risk , 2015, Stroke.

[45]  Mark Levenson,et al.  Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation , 2015, Circulation.

[46]  B. Ovbiagele,et al.  Evaluation of Cryptogenic Stroke With Advanced Diagnostic Techniques , 2014, Stroke.

[47]  Alexander Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[48]  C. Murray,et al.  Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study , 2014, Circulation.

[49]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[50]  D. Atar,et al.  Mass screening for silent atrial fibrillation in high risk patients - preliminary results from the STROKESTOP trial , 2013 .

[51]  M. Ahn,et al.  Clues to Occult Cancer in Patients with Ischemic Stroke , 2012, PloS one.

[52]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[53]  S. Yusuf,et al.  Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial , 2010, The Lancet Neurology.

[54]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[55]  M. Aguilar,et al.  Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.

[56]  J. Douketis,et al.  Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. , 2007, Archives of internal medicine.

[57]  P. Wolf,et al.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.